Safety and PK of Inhaled Nemiralisib in Healthy Subjects

Phase 1, randomised, double-blind trial of nemiralisib in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by GSK. Primary endpoints: Number of subjects with any adverse event(s) (AE) and serious adverse event(s) (SAE) up to 4 weeks, Systolic and diastolic blood pressure up to 8 weeks and 8 more. Started Mar 2016; status: completed.